Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

• Glavni autori: Lin Fan (Autor), Yuanyuan Zhang (Autor), Peter Maguire (Autor), Dominic Muston (Autor), Matthew Monberg (Autor), Jagadeswara Rao Earla (Autor), Adela Mihai (Autor), Poonam Gulati (Autor)
• Format: Knjiga
• Izdano: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Background The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated.Objective Compare PARPi-related AE management costs from a US payer perspective.Methods The frequency of treatment-related grade 3-4 A...